Move of Bayer’s Olivier Brandicourt to become Sanofi CEO confirmed
Confirming what the media had been saying most of the week, French pharma major Sanofi (Euronext: SAN) late yesterday said that Olivier Brandicourt will become the firm’s chief executive, effective April 2.
Dr Brandicourt, a Frenchman and a trained physician, is currently chairman of the board of management of Germany’s Bayer HealthCare and member of the executive council of Bayer AG (BAYN: DE), having joined Bayer in November 2013. Having begun his industrial career in 1987 at Parke-Davis/Warner-Lambert, he subsequently joined Pfizer, where he held positions of increasing responsibility, becoming a member of its Executive Leadership Team in 2010. He faces the challenge of restoring stability to Sanofi’s management after the upheaval of recent months and overseeing a series of product launches that are crucial to the company’s prospects of fresh growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze